Abbott Laboratories (NYSE:ABT) recently introduced the FreeStyle Libre 3 Plus in Canada, marking an advancement in diabetes management technology with its small, sensor-based glucose monitoring ...

"Halfway through the year, we delivered high single-digit organic sales growth, double-digit EPS growth, significantly expanded our margin profiles, and continued to advance key programs through our ...

The heat of the summer season brings a few more challenges for children living with diabetes. An expert speaks about how the ...

Q2 2025 Earnings Call Transcript July 17, 2025 Abbott Laboratories reports earnings inline with expectations. Reported EPS is ...

Abbott Laboratories (NYSE:ABT) is included among the 14 Best Pharma Dividend Stocks to Buy in 2025. Abbott Laboratories (NYSE:ABT) has long held a strong position in the heavily regulated healthcare ...

Continuous glucose monitors, small patches that provide 24-hour insight into concentrations of sugar in the blood, could be a ...

Investing.com -- Abbott Laboratories reported second-quarter earnings that slightly exceeded analyst expectations, but shares fell 2.5% following the results.

New research from investigators at Mass General Brigham suggests that a commonly used type 2 diabetes medication is linked to a higher rate of heart-related conditions compared to medications that hit ...

Sales growth in the quarter was led by double-digit growth in Diabetes Care, Heart Failure, Structural Heart, and Electrophysiology.

Detailed price information for Abbott Laboratories (ABT-N) from The Globe and Mail including charting and trades.

A quarter-size device that tracks the rise and fall of sugar in your blood is the latest source of hope — and hype — in the growing buzz around wearable health technology.